- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Severe chronic plaque psoriasis Severe psoriatic arthritis Severe Crohn disease Complex refractory fistulising Crohn disease
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Ustekinumab – March 2025
Ustekinumab; Injection 45 mg in 0.5 mL single use pre-filled syringe, Injection 90 mg in 1 mL single use pre-filled syringe, Solution concentrate for I.V. infusion 130 mg in 26 mL (5 mg per mL); Epyztek®
Last updated
12 March 2025
